Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B 1.351 Isolates in Microneutralization Assays.

Abstract

Increasing evidence suggests that some newly emerged SARS-CoV-2 variants of concern (VoCs) resist neutralization by antibodies elicited by the early-pandemic wild-type virus. We applied neutralization tests to paired recoveree sera (n = 38) using clinical isolates representing the first wave (D614G), VoC1, and VoC2 lineages (B.1.1.7 and B 1.351). Neutralizing antibodies inhibited contemporary and VoC1 lineages, whereas inhibition of VoC2 was reduced 8-fold, with 50% of sera failing to show neutralization. These results provide evidence for the increased potential of VoC2 to reinfect previously SARS-CoV-infected individuals. The kinetics of NAbs in different patients showed similar decline against all variants, with generally low initial anti-B.1.351 responses becoming undetectable, but with anti-B.1.1.7 NAbs remaining detectable (>20) for months after acute infection.

• Authors: Jenni Virtanen, Ruut Uusitalo, Essi M Korhonen, Kirsi Aaltonen, Teemu Smura, Suvi Kuivanen, Sari H Pakkanen, Sointu Mero, Anu Patjas, Marianna Riekkinen, Anu Kantele, Visa Nurmi, Klaus Hedman, Jussi Hepojoki, Tarja Sironen, Eili Huhtamo, Olli Vapalahti
• Journal: Viruses (Viruses) Vol. 13 Issue 6 (05 26 2021) ISSN: 1999-4915 [Electronic] Switzerland
• PMID: 34073577 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Neutralizing
• Antibodies, Viral
• Coronavirus Nucleocapsid Proteins
• Immunoglobulin G
• Phosphoproteins
• Spike Glycoprotein, Coronavirus
• nucleocapsid phosphoprotein, SARS-CoV-2
• spike protein, SARS-CoV-2

Topics

• Animals
• Antibodies, Neutralizing (immunology)
• Antibodies, Viral (immunology)
• COVID-19 (diagnosis, immunology, virology)
• Chlorocebus aethiops
• Coronavirus Nucleocapsid Proteins (immunology)
• Humans
• Immunoglobulin G (immunology)
• Kinetics
• Neutralization Tests
• Phosphoproteins (immunology)
• SARS-CoV-2 (genetics, immunology, isolation & purification)
• Severity of Illness Index
• Spike Glycoprotein, Coronavirus (immunology)
• Vero Cells